Reductions in glucose among postmenopausal women who use and do not use estrogen therapy

Catherine Kim, Shengchun Kong, Gail A. Laughlin, Sherita H. Golden, Kieren Mather, Bin Nan, John F. Randolph, Sharon L. Edelstein, Fernand Labrie, Elizabeth Buschur, Elizabeth Barrett-Connor

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Among postmenopausal women who do not use estrogen therapy (ET), we have previously reported that intensive lifestyle modification (ILS) leads to increases in sex hormone-binding globulin (SHBG) and that such increases are associated with reductions in fasting plasma glucose (FPG) and 2-hour postchallenge glucose (2HG). Oral ET decreases FPG and increases 2HG while increasing both SHBG and estradiol (E2). It is unknown if ILS reduces glucose among ET users, if changes in SHBG and E2 might mediate any glucose decreases in ET users, and if these patterns differ from those in non-ET users. METHODS: We conducted a secondary analysis of postmenopausal women in the Diabetes Prevention Program who used ET at baseline and 1-year follow-up (n = 324) and who did not use ET at either time point (n = 382). Participants were randomized to ILS, metformin, or placebo administered at 850 mg BID. RESULTS: ET users were younger, more often white, and more likely to have had bilateral oophorectomy than non-ET users. Among ET users, ILS reduced FPG (P < 0.01) and 2HG (P < 0.01), and metformin reduced FPG (P < 0.01) but not 2HG (P = 0.56), compared with placebo. Associations between SHBG and total E2 with FPG and 2HG were not significant among women randomized to ILS or metformin. These patterns differed from those observed among women who did not use ET. CONCLUSIONS: We conclude that among glucose-intolerant ET users, interventions to reduce glucose are effective but possibly mediated through different pathways than among women who do not use ET.

Original languageEnglish
Pages (from-to)393-400
Number of pages8
JournalMenopause
Volume20
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Estrogens
Glucose
Sex Hormone-Binding Globulin
Life Style
Fasting
Therapeutics
Metformin
Placebos
Ovariectomy
Estradiol

Keywords

  • Estrogen
  • Glucose
  • Hormone therapy
  • Menopause
  • Progestogen

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Kim, C., Kong, S., Laughlin, G. A., Golden, S. H., Mather, K., Nan, B., ... Barrett-Connor, E. (2013). Reductions in glucose among postmenopausal women who use and do not use estrogen therapy. Menopause, 20(4), 393-400. https://doi.org/10.1097/GME.0b013e3182703b73

Reductions in glucose among postmenopausal women who use and do not use estrogen therapy. / Kim, Catherine; Kong, Shengchun; Laughlin, Gail A.; Golden, Sherita H.; Mather, Kieren; Nan, Bin; Randolph, John F.; Edelstein, Sharon L.; Labrie, Fernand; Buschur, Elizabeth; Barrett-Connor, Elizabeth.

In: Menopause, Vol. 20, No. 4, 04.2013, p. 393-400.

Research output: Contribution to journalArticle

Kim, C, Kong, S, Laughlin, GA, Golden, SH, Mather, K, Nan, B, Randolph, JF, Edelstein, SL, Labrie, F, Buschur, E & Barrett-Connor, E 2013, 'Reductions in glucose among postmenopausal women who use and do not use estrogen therapy', Menopause, vol. 20, no. 4, pp. 393-400. https://doi.org/10.1097/GME.0b013e3182703b73
Kim, Catherine ; Kong, Shengchun ; Laughlin, Gail A. ; Golden, Sherita H. ; Mather, Kieren ; Nan, Bin ; Randolph, John F. ; Edelstein, Sharon L. ; Labrie, Fernand ; Buschur, Elizabeth ; Barrett-Connor, Elizabeth. / Reductions in glucose among postmenopausal women who use and do not use estrogen therapy. In: Menopause. 2013 ; Vol. 20, No. 4. pp. 393-400.
@article{5c2fa03bc3c4477f82f43e3ed4b25dd6,
title = "Reductions in glucose among postmenopausal women who use and do not use estrogen therapy",
abstract = "Among postmenopausal women who do not use estrogen therapy (ET), we have previously reported that intensive lifestyle modification (ILS) leads to increases in sex hormone-binding globulin (SHBG) and that such increases are associated with reductions in fasting plasma glucose (FPG) and 2-hour postchallenge glucose (2HG). Oral ET decreases FPG and increases 2HG while increasing both SHBG and estradiol (E2). It is unknown if ILS reduces glucose among ET users, if changes in SHBG and E2 might mediate any glucose decreases in ET users, and if these patterns differ from those in non-ET users. METHODS: We conducted a secondary analysis of postmenopausal women in the Diabetes Prevention Program who used ET at baseline and 1-year follow-up (n = 324) and who did not use ET at either time point (n = 382). Participants were randomized to ILS, metformin, or placebo administered at 850 mg BID. RESULTS: ET users were younger, more often white, and more likely to have had bilateral oophorectomy than non-ET users. Among ET users, ILS reduced FPG (P < 0.01) and 2HG (P < 0.01), and metformin reduced FPG (P < 0.01) but not 2HG (P = 0.56), compared with placebo. Associations between SHBG and total E2 with FPG and 2HG were not significant among women randomized to ILS or metformin. These patterns differed from those observed among women who did not use ET. CONCLUSIONS: We conclude that among glucose-intolerant ET users, interventions to reduce glucose are effective but possibly mediated through different pathways than among women who do not use ET.",
keywords = "Estrogen, Glucose, Hormone therapy, Menopause, Progestogen",
author = "Catherine Kim and Shengchun Kong and Laughlin, {Gail A.} and Golden, {Sherita H.} and Kieren Mather and Bin Nan and Randolph, {John F.} and Edelstein, {Sharon L.} and Fernand Labrie and Elizabeth Buschur and Elizabeth Barrett-Connor",
year = "2013",
month = "4",
doi = "10.1097/GME.0b013e3182703b73",
language = "English",
volume = "20",
pages = "393--400",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Reductions in glucose among postmenopausal women who use and do not use estrogen therapy

AU - Kim, Catherine

AU - Kong, Shengchun

AU - Laughlin, Gail A.

AU - Golden, Sherita H.

AU - Mather, Kieren

AU - Nan, Bin

AU - Randolph, John F.

AU - Edelstein, Sharon L.

AU - Labrie, Fernand

AU - Buschur, Elizabeth

AU - Barrett-Connor, Elizabeth

PY - 2013/4

Y1 - 2013/4

N2 - Among postmenopausal women who do not use estrogen therapy (ET), we have previously reported that intensive lifestyle modification (ILS) leads to increases in sex hormone-binding globulin (SHBG) and that such increases are associated with reductions in fasting plasma glucose (FPG) and 2-hour postchallenge glucose (2HG). Oral ET decreases FPG and increases 2HG while increasing both SHBG and estradiol (E2). It is unknown if ILS reduces glucose among ET users, if changes in SHBG and E2 might mediate any glucose decreases in ET users, and if these patterns differ from those in non-ET users. METHODS: We conducted a secondary analysis of postmenopausal women in the Diabetes Prevention Program who used ET at baseline and 1-year follow-up (n = 324) and who did not use ET at either time point (n = 382). Participants were randomized to ILS, metformin, or placebo administered at 850 mg BID. RESULTS: ET users were younger, more often white, and more likely to have had bilateral oophorectomy than non-ET users. Among ET users, ILS reduced FPG (P < 0.01) and 2HG (P < 0.01), and metformin reduced FPG (P < 0.01) but not 2HG (P = 0.56), compared with placebo. Associations between SHBG and total E2 with FPG and 2HG were not significant among women randomized to ILS or metformin. These patterns differed from those observed among women who did not use ET. CONCLUSIONS: We conclude that among glucose-intolerant ET users, interventions to reduce glucose are effective but possibly mediated through different pathways than among women who do not use ET.

AB - Among postmenopausal women who do not use estrogen therapy (ET), we have previously reported that intensive lifestyle modification (ILS) leads to increases in sex hormone-binding globulin (SHBG) and that such increases are associated with reductions in fasting plasma glucose (FPG) and 2-hour postchallenge glucose (2HG). Oral ET decreases FPG and increases 2HG while increasing both SHBG and estradiol (E2). It is unknown if ILS reduces glucose among ET users, if changes in SHBG and E2 might mediate any glucose decreases in ET users, and if these patterns differ from those in non-ET users. METHODS: We conducted a secondary analysis of postmenopausal women in the Diabetes Prevention Program who used ET at baseline and 1-year follow-up (n = 324) and who did not use ET at either time point (n = 382). Participants were randomized to ILS, metformin, or placebo administered at 850 mg BID. RESULTS: ET users were younger, more often white, and more likely to have had bilateral oophorectomy than non-ET users. Among ET users, ILS reduced FPG (P < 0.01) and 2HG (P < 0.01), and metformin reduced FPG (P < 0.01) but not 2HG (P = 0.56), compared with placebo. Associations between SHBG and total E2 with FPG and 2HG were not significant among women randomized to ILS or metformin. These patterns differed from those observed among women who did not use ET. CONCLUSIONS: We conclude that among glucose-intolerant ET users, interventions to reduce glucose are effective but possibly mediated through different pathways than among women who do not use ET.

KW - Estrogen

KW - Glucose

KW - Hormone therapy

KW - Menopause

KW - Progestogen

UR - http://www.scopus.com/inward/record.url?scp=84876164859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876164859&partnerID=8YFLogxK

U2 - 10.1097/GME.0b013e3182703b73

DO - 10.1097/GME.0b013e3182703b73

M3 - Article

VL - 20

SP - 393

EP - 400

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 4

ER -